Anthony G. Letai

This study identifies common survival mechanisms between drug-tolerant persisters and immunotherapy persisters, showing they share reduced mitochondrial apoptotic sensitivity and cross-resistance to therapies.

This paper uses Dynamic BH3 Profiling to predict clinical outcomes in AML by assessing drug-induced apoptotic priming in patient samples.

This study identifies that TP53 mutations in AML lead to resistance to VenAza therapy by blocking caspase-3/7 activation after mitochondrial outer membrane permeabilization.